Core Viewpoint - Crexendo (CXDO) has shown a significant price increase of 24.2% over the past four weeks, with analysts suggesting further upside potential based on a mean price target of $8.30, indicating a 42.9% increase from the current price of $5.81 [1] Price Targets and Analyst Estimates - The mean price target consists of five short-term estimates with a standard deviation of $0.97, where the lowest estimate is $7.50 (29.1% increase) and the highest is $10 (72.1% increase) [2] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Consensus - Analysts have shown increasing optimism about CXDO's earnings prospects, with a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, two earnings estimates have been revised upward, leading to an 18.2% increase in the Zacks Consensus Estimate for the current year [12] Zacks Rank and Investment Potential - CXDO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside in the near term [13]

uniQure (QURE) closed the last trading session at $12.81, gaining 32.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $33.50 indicates a 161.5% upside potential.The average comprises 10 short-term price targets ranging from a low of $20 to a high of $70, with a standard deviation of $15.33. While the lowest estimate indicates an increase of 56.1% from the current price level, the ...

Core Viewpoint - BioLife Solutions, Inc. (BLFS) shares have increased by 8.2% recently, with a mean price target of $31.22 suggesting a potential upside of 30.7% from the current price of $23.89 [1] Price Targets and Analyst Estimates - The mean estimate consists of nine short-term price targets with a standard deviation of $1.48, indicating variability among analysts [2] - The lowest price target is $30, representing a 25.6% increase, while the highest target is $34, indicating a potential surge of 42.3% [2] - A low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Sentiment - Analysts are optimistic about BLFS's earnings prospects, as indicated by a positive trend in earnings estimate revisions [4][11] - The Zacks Consensus Estimate for the current year has risen by 19.2% over the past month, with no negative revisions [12] - BLFS holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13]

Core Viewpoint - AudioEye (AEYE) shares have increased by 14.3% in the past four weeks, closing at $12.90, with a potential upside indicated by Wall Street analysts' price targets suggesting a mean estimate of $22.40, representing a 73.6% increase from the current price [1] Price Targets and Analyst Estimates - The mean estimate consists of five short-term price targets with a standard deviation of $2.51, where the lowest estimate of $20 indicates a 55% increase, and the highest estimate suggests a 93.8% surge to $25 [2] - A low standard deviation among price targets indicates a high degree of agreement among analysts regarding the stock's price movement direction and magnitude [9] Earnings Estimates and Analyst Sentiment - Analysts show strong agreement in revising earnings per share (EPS) estimates higher, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has risen by 10.4% over the past month, with one estimate increasing and no negative revisions [12] - AEYE holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential upside [13]

Shares of Beyond (BYON) have gained 30.8% over the past four weeks to close the last trading session at $5.01, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $12.83 indicates a potential upside of 156.1%.The mean estimate comprises six short-term price targets with a standard deviation of $12.16. While the lowest estimate of $5 indicates a 0.2% decline from the current price le ...

Core Viewpoint - Honest (HNST) shares have increased by 14.5% in the past four weeks, closing at $5.07, with a potential upside indicated by Wall Street analysts' mean price target of $7.14, suggesting a 40.8% increase from the current price [1] Price Targets and Analyst Estimates - The mean estimate consists of seven short-term price targets with a standard deviation of $0.85, where the lowest estimate is $5.50 (8.5% increase) and the highest is $8 (57.8% increase) [2] - A low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Optimism - Analysts are optimistic about HNST's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which has shown a strong correlation with near-term stock price movements [11] - The Zacks Consensus Estimate for the current year has risen by 47.6% over the past month, with two estimates increasing and no negative revisions [12] - HNST holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for upside [13]

Shares of Kemper (KMPR) have gained 12.8% over the past four weeks to close the last trading session at $65.52, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $82.20 indicates a potential upside of 25.5%.The mean estimate comprises five short-term price targets with a standard deviation of $5.72. While the lowest estimate of $75 indicates a 14.5% increase from the current price ...

Group 1 - Mind Medicine (MindMed) Inc. (MNMD) closed at $6.45, with a 16.2% gain over the past four weeks, and a mean price target of $24.50 suggests a 279.8% upside potential [1] - The average of 10 short-term price targets ranges from a low of $16 to a high of $55, with a standard deviation of $12.13, indicating a potential increase of 148.1% to 752.7% from the current price [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price movements, as the Zacks Consensus Estimate for the current year has increased by 1.4% over the past month [11][12] Group 2 - MNMD holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a solid potential upside [13] - The consensus price target, while not entirely reliable, suggests a positive direction for price movement, supported by analysts' growing optimism regarding the company's earnings prospects [4][11]

Core Viewpoint - Centrus Energy Corp. (LEU) has shown a significant price increase of 46% over the past four weeks, with a mean price target of $148.33 indicating a potential upside of 56.6% from the current price of $94.71 [1] Price Targets and Analyst Consensus - The average price target for LEU includes six short-term estimates, ranging from a low of $69 to a high of $300, with a standard deviation of $79.84, indicating variability in analyst estimates [2] - The lowest estimate suggests a decline of 27.2%, while the highest points to a potential upside of 216.8% [2] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Optimism - Analysts are optimistic about LEU's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which has shown a 9.9% increase in the Zacks Consensus Estimate over the past month [11][12] - The company currently holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are often sought after by investors, they can be misleading and should not be the sole basis for investment decisions [3][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Viewpoint - 10x Genomics (TXG) shares have increased by 14.7% recently, with a mean price target of $14.79 suggesting a potential upside of 55.9% from the current price of $9.49 [1][2] Price Targets and Analyst Estimates - The mean estimate consists of 14 short-term price targets with a standard deviation of $3.79, indicating variability among analysts [2] - The lowest estimate of $11 indicates a 15.9% increase, while the highest estimate suggests a 174% surge to $26 [2] - Analysts' price targets can often mislead investors, as empirical research shows they rarely indicate actual stock price movements [7][10] Earnings Estimates and Analyst Agreement - Analysts are optimistic about TXG's earnings prospects, with a strong consensus on higher EPS estimates, which correlates with potential stock price increases [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 14.6%, with five estimates moving higher and no negative revisions [12] - TXG holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13]